జర్నల్ ఆఫ్ క్లినికల్ అండ్ ఎక్స్పెరిమెంటల్ ఆప్తాల్మాలజీ
అందరికి ప్రవేశం

నైరూప్య

Retrospective Study of Periocular Non Melanoma Skin Cancer Treated with the Combination of IFN alpha2b and Gamma (HeberPAG)

Garcia-Vega Yanelda, Anasagasti-Angulo Lorenzo, Valenzuela-Silva Carmen, Navarro-Mestre Marianlie, Maribeth-Ordoñez Sintia, Acosta-Medina Doraiquis, Rodríguez-Garcia MA, Collazo-Caballero Sonia, Tijerino-Arrieta Edgar, Duncan-Roberts Yaquelin, Arteaga-Hernández Ernesto, Jiménez- Barban Yanisel, Vila-Pinillo Dayami, Torres-

Background: Non-melanoma skin cancer can cause considerable morbidity when located on the eyelids and periocular skin. Basal cell carcinoma is the commonest periocular malignancy and although metastases are extremely rare, local invasion can cause significant and sometimes severe morbidity. Interferons may provide a nonsurgical approach to the management of these tumors. The aim of this work was to evaluate retrospectively, the effect of a formulation containing IFNs alpha2b and gamma in synergistic proportions (HeberPAG) on patients with periocular NMSC. Methods: The patients were identified from the data base from Department of Peripheral Tumors at “National Institute of Oncology and Radiobiology” in Havana; Dermatological Department at “Hermanos Ameijeiras” and “Enrique Cabrera” Hospitals; and policlinics from rural zone in Mayabeque; Cuba. The applications of IFN combination were practiced by medical doctors specialized in dermato-oncology. The employed doses for IFN combination were from 0.875 × 106 IU to 27 × 106 IU. Results: The series include 18 basal cell carcinoma and 3 squamous cell carcinoma of the skin with predominant clinical forms mixed (33.3%) and nodular (38.1%), 3 cases were terebrant, 2 ulcerated and 1 pigmented. The median time of tumor evolution was 16.5 months with an initial diameter of 8.25 cm. At week 12 after the end of treatment, a 47.6% complete response rate was obtained. A partial response was achieved in 5 patients (23.8%). A high response rate was obtained with overall response (CR+PR) in 71.4%. All patients reported at least 1 adverse event. The most frequent (>20%) were fever, chills, anorexia, cephalea, perilesional erythema and edema, asthenia, arthralgia and general discomfort. Conclusions: HeberPAG is an alternative useful to surgery in patients with periocular non-melanoma skin cancer when other therapies have failed or are not possible. The encouraging result justifies further confirmatory trials in periocular region.